{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Yes (Treatment-emergent ADAs)"},{"measurements":[{"groupId":"OG000","value":"72"}],"title":"No (Negative baseline and post baseline results)"},{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Not evaluable (Positive baseline results)"},{"measurements":[{"groupId":"OG000","value":"7"}],"title":"Missing (No post baseline results available)"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"81"}],"units":"Participants"}],"description":"The Anti-MOR00208 Antibodies were investigated by quantifying serum drug levels at baseline and after repeated intravenous (IV) administrations planned for up to 24 treatment cycles using sparse sampling. Anti-MOR00208 antibody sample (pre-dose only) were taken in odd numbered additional treatment cycles only (e.g., treatment Cycles 13, 15,17, 19, 21,23).","groups":[{"description":"MOR00208:\n\nMOR00208 was administered via IV infusion at a dose of 12 mg/kg. For the first three cycles (Cycles 1 to 3) of the study each cycle consisted of a MOR00208 infusion on Day 1, Day 8, Day 15 and Day 22 of the cycle.\n\nAdditionally, a loading dose was administered on Day 4 of Cycle 1. Thereafter MOR00208 was administered on a bi-weekly (every 14 days) basis with infusions on Day 1 and Day 15 of each 28-day cycle.\n\nLEN:\n\nParticipants self-administered a starting dose of 25 mg oral LEN daily on Days 1-21 of each cycle, for up to 12 cycles in total. LEN dose could be modified in a de-escalating fashion or discontinued based upon clinical and laboratory findings.\n\nOn days when both study drugs were given together, LEN was administered prior to MOR00208.","id":"OG000","title":"Tafasitamab (MOR00208) + Lenalidomide (LEN)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Immunogenicity analysis set (IAS): The IAS included participants who had at least one anti-MOR00208 antibody assessment.","reportingStatus":"POSTED","timeFrame":"Baseline, Up to a maximum of 23 cycles.","title":"Number of Participants Who Developed Anti-MOR00208 Antibodies","type":"SECONDARY","unitOfMeasure":"Participants"}